Sevilla

• Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain study Ended recruitment
  2023-509923-42-00 4 2017-07-06 HER2- positive breast cancer
• A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Ended recruitment
  2023-506390-35-00 1 2017-04-19 Patients with Advanced Solid Tumors
• Phase I-II trial of sunitinib and/or nivolumab plus chemotherapy in advanced soft tissue and bone sarcomas Ended recruitment
  2024-514776-40-00 9 2017-03-23 Advanced soft tissue and bone sarcomas
• A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723 … Ended recruitment
  2023-506144-16-00 7 2016-12-06 Advanced Stage Solid Tumors
• CheckMate 274 Ended recruitment
  2022-500630-29-00 5 2016-05-06 Subjects with High Risk Invasive Urothelial Carcinoma
• An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended recruitment
  2023-505246-26-00 5 2016-01-27 High- or very-high risk, localized or locally advanced prostate cancer
• Study to Evaluate Imetelstat (GRN163L) in Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Ended recruitment
  2024-511348-25-00 10 2015-12-11 Myelodysplastic syndromes (MDS)
• PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers … Ended recruitment
  2024-514841-12-00 5 2015-10-27 To determine whether the addition of palbociclib to adjuvant endocrine
• Study to evaluate the effectiveness of a combination of 3 treatments, followed by transplantation of their own blood cell progenitor cells f … Ended recruitment
  2024-516908-42-00 4 2015-06-15 Smoldering multiple myeloma with high risk of progression to symptomat
• Further 2 years of adjuvant imatinib may improve recurrence-free survival (RFS) of patients who are at a high risk of GIST recurrence despit … Ended recruitment
  2024-512243-23-00 5 2014-11-07 gastrointestinal stromal tumor
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• A phase Ib/II, multicenter, study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer Ended recruitment
  2023-509511-84-00 9 2014-03-19 Advanced HR+ breast cancer
• A two-year, double-blind, randomized, multicenter, active controlled Core Phase study to evaluate the safety and efficacy of fingolimod admi … Ended recruitment
  2023-507556-68-00 5 2013-07-26 Multiple Sclerosis
• "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone … Ended recruitment
  2024-515368-29-00 5 2012-09-20 patients with node positive breast cancer who do not have high Recurre
• Corticotrophin Releasing Factor 2 Agonist For the Treatment of Worsening Heart Failure (WHF) – The CRAFT-WHF Study Halted
  2024-518951-52-00 4 2025-11-12 Worsening Heart Failure
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors Halted
  2024-512927-36-00 1 2025-10-30 Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
• A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory A … Halted
  2024-516641-39-00 7 2024-12-02 Acute Myeloid Leukemia
• Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma Halted
  2023-510560-12-00 4 2024-10-03 High-risk smoldering multiple myeloma
• A study to evaluate novel immunotherapy combinations in participants with advanced non-small cell lung cancer (NSCLC) Halted
  2023-508730-34-00 9 2024-07-10 Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where par
• A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine … Halted
  2023-505829-14-00 5 2023-12-22 First recurrence glioblastoma
• A Phase 3 study to assess the immune response and safety of rMenB+OMV NZ in primed healthy participants (10 to 20 years old) Ended
  2024-519549-31-00 5 2025-09-05 Invasive meningococcal disease (IMD)
• Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection Ended
  2024-519856-94-00 4 2025-08-18 Cystic fibrosis
• Phase 2 Open Label Prospective Dose-Ranging Clinical Trial with Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacok … Ended
  2024-510582-42-02 4 2025-08-14 Acute graft versus host disease (aGvHD)
• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis Ended
  2024-513440-29-00 10 2025-06-25 Sickle cell disease vaso-occlusive crisis

Showing 1,225–1,248 of 1,630 trials